Existing healthcare investors may lack sufficient capital to bridge portfolio companies to key commercial and regulatory milestones. As a result, their portfolios may be exposed to punitive financings that have become more commonplace in recent years, compromising returns to limited and general partners.

Annex funding can protect the portfolio by providing capital to see existing investments through to liquidity and avoiding the detrimental implications of an inability to participate in future financings. Bio Equity provides annex funding for investors to meet follow-on financing requirements for existing portfolio companies.